These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

605 related items for PubMed ID: 22550315

  • 1. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials.
    Manzi S, Sánchez-Guerrero J, Merrill JT, Furie R, Gladman D, Navarra SV, Ginzler EM, D'Cruz DP, Doria A, Cooper S, Zhong ZJ, Hough D, Freimuth W, Petri MA, BLISS-52 and BLISS-76 Study Groups.
    Ann Rheum Dis; 2012 Nov; 71(11):1833-8. PubMed ID: 22550315
    [Abstract] [Full Text] [Related]

  • 2. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.
    Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzová D, Sanchez-Guerrero J, Schwarting A, Merrill JT, Chatham WW, Stohl W, Ginzler EM, Hough DR, Zhong ZJ, Freimuth W, van Vollenhoven RF, BLISS-76 Study Group.
    Arthritis Rheum; 2011 Dec; 63(12):3918-30. PubMed ID: 22127708
    [Abstract] [Full Text] [Related]

  • 3. Organ system improvements in Japanese patients with systemic lupus erythematosus treated with belimumab: A subgroup analysis from a phase 3 randomized placebo-controlled trial.
    Tanaka Y, Bass D, Chu M, Egginton S, Ji B, Roth D.
    Mod Rheumatol; 2020 Mar; 30(2):313-320. PubMed ID: 31199180
    [Abstract] [Full Text] [Related]

  • 4. Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.
    Petri MA, van Vollenhoven RF, Buyon J, Levy RA, Navarra SV, Cervera R, Zhong ZJ, Freimuth WW, BLISS-52 and BLISS-76 Study Groups.
    Arthritis Rheum; 2013 Aug; 65(8):2143-53. PubMed ID: 23754628
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.
    Navarra SV, Guzmán RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, Li EK, Thomas M, Kim HY, León MG, Tanasescu C, Nasonov E, Lan JL, Pineda L, Zhong ZJ, Freimuth W, Petri MA, BLISS-52 Study Group.
    Lancet; 2011 Feb 26; 377(9767):721-31. PubMed ID: 21296403
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison.
    Brunner HI, Abud-Mendoza C, Mori M, Pilkington CA, Syed R, Takei S, Viola DO, Furie RA, Navarra S, Zhang F, Bass DL, Eriksson G, Hammer AE, Ji BN, Okily M, Roth DA, Quasny H, Ruperto N.
    RMD Open; 2021 Sep 26; 7(3):. PubMed ID: 34531304
    [Abstract] [Full Text] [Related]

  • 7. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus.
    Wallace DJ, Stohl W, Furie RA, Lisse JR, McKay JD, Merrill JT, Petri MA, Ginzler EM, Chatham WW, McCune WJ, Fernandez V, Chevrier MR, Zhong ZJ, Freimuth WW.
    Arthritis Rheum; 2009 Sep 15; 61(9):1168-78. PubMed ID: 19714604
    [Abstract] [Full Text] [Related]

  • 8. Novel evidence-based systemic lupus erythematosus responder index.
    Furie RA, Petri MA, Wallace DJ, Ginzler EM, Merrill JT, Stohl W, Chatham WW, Strand V, Weinstein A, Chevrier MR, Zhong ZJ, Freimuth WW.
    Arthritis Rheum; 2009 Sep 15; 61(9):1143-51. PubMed ID: 19714615
    [Abstract] [Full Text] [Related]

  • 9. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response.
    van Vollenhoven RF, Petri MA, Cervera R, Roth DA, Ji BN, Kleoudis CS, Zhong ZJ, Freimuth W.
    Ann Rheum Dis; 2012 Aug 15; 71(8):1343-9. PubMed ID: 22337213
    [Abstract] [Full Text] [Related]

  • 10. The role of baseline BLyS levels and type 1 interferon-inducible gene signature status in determining belimumab response in systemic lupus erythematosus: a post hoc meta-analysis.
    Wilkinson C, Henderson RB, Jones-Leone AR, Flint SM, Lennon M, Levy RA, Ji B, Bass DL, Roth D.
    Arthritis Res Ther; 2020 May 04; 22(1):102. PubMed ID: 32366280
    [Abstract] [Full Text] [Related]

  • 11. Long-Term Safety and Efficacy of Belimumab in Patients With Systemic Lupus Erythematosus: A Continuation of a Seventy-Six-Week Phase III Parent Study in the United States.
    Furie RA, Wallace DJ, Aranow C, Fettiplace J, Wilson B, Mistry P, Roth DA, Gordon D.
    Arthritis Rheumatol; 2018 Jun 04; 70(6):868-877. PubMed ID: 29409143
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and Safety of Subcutaneous Belimumab in Anti-Double-Stranded DNA-Positive, Hypocomplementemic Patients With Systemic Lupus Erythematosus.
    Doria A, Stohl W, Schwarting A, Okada M, Scheinberg M, van Vollenhoven R, Hammer AE, Groark J, Bass D, Fox NL, Roth D, Gordon D.
    Arthritis Rheumatol; 2018 Aug 04; 70(8):1256-1264. PubMed ID: 29671280
    [Abstract] [Full Text] [Related]

  • 13. Belimumab: review of use in systemic lupus erythematosus.
    Boyce EG, Fusco BE.
    Clin Ther; 2012 May 04; 34(5):1006-22. PubMed ID: 22464040
    [Abstract] [Full Text] [Related]

  • 14. Belimumab for the treatment of systemic lupus erythematosus.
    Jordan N, D'Cruz DP.
    Expert Rev Clin Immunol; 2015 Feb 04; 11(2):195-204. PubMed ID: 25543845
    [Abstract] [Full Text] [Related]

  • 15. Changes in quality of life in relation to disease activity in systemic lupus erythematosus: post-hoc analysis of the BLISS-52 Trial.
    Jolly M, Annapureddy N, Arnaud L, Devilliers H.
    Lupus; 2019 Dec 04; 28(14):1628-1639. PubMed ID: 31674267
    [Abstract] [Full Text] [Related]

  • 16. Belimumab: in systemic lupus erythematosus.
    Burness CB, McCormack PL.
    Drugs; 2011 Dec 24; 71(18):2435-44. PubMed ID: 22141386
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study.
    Stohl W, Schwarting A, Okada M, Scheinberg M, Doria A, Hammer AE, Kleoudis C, Groark J, Bass D, Fox NL, Roth D, Gordon D.
    Arthritis Rheumatol; 2017 May 24; 69(5):1016-1027. PubMed ID: 28118533
    [Abstract] [Full Text] [Related]

  • 18. Elevated BLyS levels in patients with systemic lupus erythematosus: Associated factors and responses to belimumab.
    Roth DA, Thompson A, Tang Y, Hammer AE, Molta CT, Gordon D.
    Lupus; 2016 Apr 24; 25(4):346-54. PubMed ID: 26385220
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials.
    Clowse ME, Wallace DJ, Furie RA, Petri MA, Pike MC, Leszczyński P, Neuwelt CM, Hobbs K, Keiserman M, Duca L, Kalunian KC, Galateanu C, Bongardt S, Stach C, Beaudot C, Kilgallen B, Gordon C, EMBODY Investigator Group.
    Arthritis Rheumatol; 2017 Feb 24; 69(2):362-375. PubMed ID: 27598855
    [Abstract] [Full Text] [Related]

  • 20. Low-dose belimumab for patients with systemic lupus erythematosus at low disease activity: protocol for a multicentre, randomised, double-blind, placebo-controlled clinical trial.
    Sun F, Huang W, Chen J, Zhao L, Zhang D, Wang X, Wan W, Dai SM, Chen S, Li T, Ye S.
    Lupus Sci Med; 2022 Feb 24; 9(1):. PubMed ID: 35105722
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.